•
•
•
•
•
•
•
•
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Yahoo
35.48%
Finnhub
22.58%
gurufocus.com
12.9%
Others
29.03%
Country
US
Industry
Health Care
Market Cap
Mid Cap
Num. Employees
1402
IPO Date
Jun 20, 2013
Country
US
Industry
Health Care
PTC Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in South Plainfield, New Jersey and currently employs 1,402 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Its portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology. The firm has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The company also offers Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, and Evrysdi, a treatment for spinal muscular atrophy (SMA). Its splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease (HD).
PTC Therapeutics on Monday announced a global licensing and collaboration agreement with Novartis (NVS) for its Huntington’s Disease program, PTC518, under which PTC will receive $1B at closing and is eligible for up to $1.9B in development, regulatory and sales milestones, the analyst tells investors in a research note.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Related Stocks
Related Stocks
Stocks being mentioned with PTCT
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Low Data